PomDoctor Ltd. Unsponsored ADR (POM) AI Stock Analysis

• Market Cap: $29.56M
• Dividend Yield: N/A
• Average Volume (3M): 2.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 106,192,310
• 10 Day Avg. Volume: 781,994
• 30 Day Avg. Volume: 2,198,746
• PEG Ratio: 14.95
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 10.17
• P/FCF Ratio: -215.48
• Enterprise Value/Market Cap: 20.71
• Enterprise Value/Revenue: 0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: 0.08
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.22 ▼(-28.06% Downside)
• Action: Upgraded Date: 01/22/26
• Date: Action: Upgraded 01/22/26

The score is driven primarily by weak financial fundamentals (persistent losses and negative equity) and bearish technical momentum (negative MACD, price below key moving averages). Valuation impact is limited because P/E and dividend data were not provided.

Positive Factors

Insurance integration / reimbursement access

Embedding national and local insurance payment into its app/WeChat mini-program creates durable reimbursement access, improving patient affordability and retention. This structural integration raises barriers to entry, increases platform stickiness, and supports scalable, reimbursable chronic-care volumes over time.

Pharma partnerships / supply advantages

Direct partnerships with domestic pharma secure access to patented drugs, favorable purchase terms and rebates, and reduce reliance on intermediaries. That strengthens pricing and supply reliability, improves margins potential, and supports differentiated product breadth and distribution as the online hospital channel scales sustainably.

Revenue growth and capital support

Sustained top-line growth, driven by an 83% surge in online pharmacy, indicates strong product-market fit in digital drug distribution. Combined with fresh IPO capital, the company has runway to invest in technology, partnerships and geographic expansion, supporting continued structural revenue expansion over the medium term.

Negative Factors

Negative equity / weak balance sheet

Negative shareholders' equity and liabilities above assets signal deep solvency risk and constrained financial flexibility. Over the medium term this raises refinancing risk, limits ability to fund R&D or M&A internally, and can force dilutive financing or asset sales to stabilize the balance sheet.

Persistent unprofitability and thin gross margin

Wide negative net margins and low gross margins show the company struggles to convert sales into sustainable profits. In healthcare, low gross margin reduces room for R&D and commercialization spend; without margin improvement, long-term viability depends on structural cost or pricing shifts that are not yet evident.

Negative operating cash flow / cash conversion issues

Despite FCF improvement, persistent negative operating cash flow and poor OCF-to-income conversion indicate operational cash burn. This undermines internal funding of growth, increases dependence on external capital, and elevates execution risk if capital markets tighten or additional financing becomes costly.

PomDoctor Ltd. Unsponsored ADR Business Overview & Revenue Model

Company Description

Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.

How the Company Makes Money

PomDoctor generates revenue through multiple channels, primarily from the sale of its pharmaceutical products and medical devices. The company engages in direct sales to healthcare providers, hospitals, and clinics, which constitute a significant portion of its revenue. Additionally, PomDoctor may enter into licensing agreements with larger pharmaceutical companies for its proprietary technologies, providing a steady stream of royalty income. The company also seeks to expand its earnings through strategic partnerships with research institutions and healthcare organizations, which can lead to joint ventures and collaborative projects in drug development and clinical trials. Government grants and funding for research initiatives further contribute to its financial stability.

PomDoctor Ltd. Unsponsored ADR Financial Statement Overview

Summary

Financial performance is weak. Revenue grew 12.37%, but profitability is poor (net margin -41.85%, EBIT margin -7.12%) and the balance sheet is high risk with negative equity and liabilities exceeding assets. Cash flow shows some improvement in free cash flow growth (64.78%) but operating cash flow remains negative.

Income Statement

PomDoctor Ltd. has shown a moderate revenue growth rate of 12.37% in the most recent year, indicating some potential for expansion. However, the company is struggling with profitability, as evidenced by negative net profit margins (-41.85%) and EBIT margins (-7.12%). The gross profit margin is relatively low at 13.92%, reflecting challenges in cost management or pricing power.

Balance Sheet

The balance sheet reveals significant financial instability, with a negative stockholders' equity and a concerning debt-to-equity ratio of -0.19. The return on equity is positive at 6.33%, but this is due to negative equity, which is a red flag. The equity ratio is negative, indicating that liabilities exceed assets, posing a risk to financial health.

Cash Flow

The cash flow statement shows improvement in free cash flow growth at 64.78%, suggesting better cash management. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is -0.09, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is aligned with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	41.40B	342.56M	304.85M	245.22M	215.38M
Gross Profit	26.59B	47.69M	38.72M	54.86M	52.51M
EBITDA	7.63B	-24.27M	-22.99M	-3.81M	-58.58M
Net Income	1.71B	-143.36M	-145.39M	-125.51M	-188.40M
Balance Sheet
Total Assets	124.68B	46.23M	66.31M	48.62M	19.31M
Cash, Cash Equivalents and Short-Term Investments	2.11B	7.65M	6.72M	2.49M	2.17M
Total Debt	37.66B	441.10M	413.29M	361.24M	341.26M
Total Liabilities	92.19B	2.14B	2.03B	1.95B	1.80B
Stockholders Equity	32.48B	-2.26B	-2.12B	-1.97B	-1.85B
Cash Flow
Free Cash Flow	-31.00M	-16.17M	-45.91M	-22.02M	-15.68M
Operating Cash Flow	5.37B	-16.13M	-45.80M	-22.02M	-15.68M
Investing Cash Flow	-5.51B	-33.37K	-111.89K	0.00	-500.00K
Financing Cash Flow	1.80B	17.02M	50.07M	22.49M	5.44M

PomDoctor Ltd. Unsponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LFMD	49 Neutral	$128.52M	-16.13	―	―	30.71%	73.43%
YI	48 Neutral	$71.74M	-7.41	―	―	-7.46%	73.05%
POM	41 Neutral	$29.56M	―	―	―	―	―
PETS	41 Neutral	$60.14M	-0.89	-100.61%	―	-24.81%	-5344.15%

PomDoctor Ltd. Unsponsored ADR Corporate Events

Pomdoctor Deepens Medical Insurance Integration to Expand Online Chronic-Care Reach Across Major Chinese Cities

On February 4, 2026, Pomdoctor Limited announced a strategic expansion of its integration with China’s national and local medical insurance systems across major cities, aiming to broaden market reach and enhance its online chronic-care services. Building on more than two years of experience supporting insured outpatient settlements for chronic and special disease patients in Guangzhou, the company plans to extend similar capabilities to other Greater Bay Area cities such as Foshan, Zhuhai, Shenzhen, Dongguan, and Huizhou, as well as key municipalities including Beijing, Shanghai, Tianjin, and regional hubs like Chengdu, Xi’an, Nanjing, Hangzhou, and Fuzhou. By embedding insurance payment functionalities into its app and WeChat mini-program, Pomdoctor is strengthening its competitive position in China’s increasingly standardized and scaled internet healthcare sector, offering patients faster, reimbursable online consultations and home-delivered medications, while potentially driving scalable growth and deeper ecosystem integration for its platform and partners.

The most recent analyst rating on (POM) stock is a Hold with a $0.22 price target. To see the full list of analyst forecasts on PomDoctor Ltd. Unsponsored ADR stock, see the POM Stock Forecast page.

Pomdoctor Receives Nasdaq Deficiency Notice Over Minimum Bid Price

On February 2, 2026, Pomdoctor Limited announced that it received a Nasdaq notice dated January 29, 2026, stating that the company’s American depositary shares had traded below the US$1.00 minimum bid price requirement for 33 consecutive business days, putting it out of compliance with Nasdaq’s listing rules. The notice does not immediately affect the listing or trading of Pomdoctor’s ADSs, and the company has been granted a 180-day compliance period until July 28, 2026, to regain compliance, with the possibility of additional time subject to Nasdaq’s determination; Pomdoctor said the deficiency letter will not impact its business operations and that it will take reasonable measures to restore compliance, a development that puts its share price under scrutiny but leaves its underlying online healthcare operations unaffected for now.

The most recent analyst rating on (POM) stock is a Hold with a $0.22 price target. To see the full list of analyst forecasts on PomDoctor Ltd. Unsponsored ADR stock, see the POM Stock Forecast page.

Pomdoctor Deepens Pharma Partnerships to Drive Internet Hospital Expansion in China

On January 16, 2026, Pomdoctor Limited reported significant progress in its strategic collaborations with several leading domestic pharmaceutical companies, including Jiangsu Haosoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical and Eddingpharm, aimed at accelerating the growth of its internet hospital business in China’s rapidly expanding online drug sales market. These partnerships give Pomdoctor direct access to innovative and patented drugs, favorable purchase terms and performance-based rebates, while providing pharmaceutical manufacturers with a more efficient, data-driven distribution channel that reduces reliance on traditional intermediaries, enhances channel control and supports more targeted marketing. Management framed the model as a “win‑win” supply-chain collaboration that strengthens Pomdoctor’s competitiveness on quality and pricing, broadens product choice for pharmacies and patients, and aligns the company with broader healthcare reforms that are pushing China’s pharmaceutical distribution system toward flatter, more digital and patient‑centric structures.

The most recent analyst rating on (POM) stock is a Sell with a $0.30 price target. To see the full list of analyst forecasts on PomDoctor Ltd. Unsponsored ADR stock, see the POM Stock Forecast page.

Pomdoctor Limited Reports Strong Revenue Growth Amidst Challenging Conditions

Pomdoctor Limited announced its unaudited financial results for the first half of fiscal 2025, ending June 30, 2025. Despite a challenging economic environment, the company reported a 16.2% increase in net revenue, driven by an 83.2% growth in online pharmacy businesses. The company maintained a stable gross profit margin of 16.2% while managing higher sales and marketing expenses. The successful IPO in October provided additional capital, supporting future growth and strategic initiatives.